Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies

Trades of Eli Lilly shares were made on Donald Trump's behalf, with hundreds of thousands of dollars invested in the company, which benefited from his administration's policies to expand access to obesity treatments. The trades were part of a larger set of transactions worth between $220m and $750m. These transactions occurred in the first quarter of 2026.